These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 18362865

  • 1. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
    Schwartz JL, Kovalevsky G, Lai JJ, Ballagh SA, McCormick T, Douville K, Mauck CK, Callahan MM.
    Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
    [Abstract] [Full Text] [Related]

  • 2. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
    Bunge K, Macio I, Meyn L, Noguchi L, Parniak MA, Schwartz JL, Moncla B, Hillier S.
    J Acquir Immune Defic Syndr; 2012 Aug 01; 60(4):337-43. PubMed ID: 22495787
    [Abstract] [Full Text] [Related]

  • 3. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC.
    AIDS; 2009 Jul 31; 23(12):1531-8. PubMed ID: 19550287
    [Abstract] [Full Text] [Related]

  • 4. Fourteen-day safety and acceptability study of the universal placebo gel.
    Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, Callahan MM.
    Contraception; 2007 Feb 31; 75(2):136-41. PubMed ID: 17241844
    [Abstract] [Full Text] [Related]

  • 5. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
    Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L, HPTN 050 Protocol Team.
    AIDS; 2006 Feb 28; 20(4):543-51. PubMed ID: 16470118
    [Abstract] [Full Text] [Related]

  • 6. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
    El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, Soto-Torres L, Kwiecien A.
    AIDS; 2006 May 12; 20(8):1109-16. PubMed ID: 16691061
    [Abstract] [Full Text] [Related]

  • 7. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
    Ballagh SA, Brache V, Mauck C, Callahan MM, Cochon L, Wheeless A, Moench TR.
    Contraception; 2008 Feb 12; 77(2):130-7. PubMed ID: 18226678
    [Abstract] [Full Text] [Related]

  • 8. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
    Haaland RE, Evans-Strickfaden T, Holder A, Pau CP, McNicholl JM, Chaikummao S, Chonwattana W, Hart CE.
    Antimicrob Agents Chemother; 2012 Jul 12; 56(7):3592-6. PubMed ID: 22508307
    [Abstract] [Full Text] [Related]

  • 9. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.
    Ventuneac A, Carballo-Diéguez A, McGowan I, Dennis R, Adler A, Khanukhova E, Price C, Saunders T, Siboliban C, Anton P.
    AIDS Behav; 2010 Jun 12; 14(3):618-28. PubMed ID: 19757017
    [Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
    Kilmarx PH, Blanchard K, Chaikummao S, Friedland BA, Srivirojana N, Connolly C, Witwatwongwana P, Supawitkul S, Mock PA, Chaowanachan T, Tappero J.
    Sex Transm Dis; 2008 Mar 12; 35(3):226-32. PubMed ID: 18490865
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
    Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Giguere JF, Domingo MC, Piret J, Tsague L, Zekeng L, Mwatha A, Mâsse B, Bergeron MG.
    Contraception; 2009 Nov 12; 80(5):484-92. PubMed ID: 19835725
    [Abstract] [Full Text] [Related]

  • 12. Design of tenofovir-UC781 combination microbicide vaginal gels.
    Kiser PF, Mahalingam A, Fabian J, Smith E, Damian FR, Peters JJ, Katz DF, Elgendy H, Clark MR, Friend DR.
    J Pharm Sci; 2012 May 12; 101(5):1852-64. PubMed ID: 22359356
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
    Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, Marci R, Cosmi E.
    Menopause; 2004 May 12; 11(1):49-56. PubMed ID: 14716182
    [Abstract] [Full Text] [Related]

  • 14. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
    van de Wijgert JH, Kilmarx PH, Jones HE, Karon JM, Chaikummao S.
    Contraception; 2008 Feb 12; 77(2):122-9. PubMed ID: 18226677
    [Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.
    Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z.
    Clin Infect Dis; 2001 Feb 01; 32(3):476-82. PubMed ID: 11170957
    [Abstract] [Full Text] [Related]

  • 16. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
    Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I.
    PLoS One; 2011 Feb 01; 6(9):e23243. PubMed ID: 21969851
    [Abstract] [Full Text] [Related]

  • 17. Safety evaluation of 1% tenofovir gel in healthy men.
    Schwartz JL, Poindexter A, Wheeless A, Mauck CK, Callahan MM.
    Int J STD AIDS; 2009 Jun 01; 20(6):384-6. PubMed ID: 19451321
    [Abstract] [Full Text] [Related]

  • 18. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
    Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R.
    Contraception; 2004 Sep 01; 70(3):233-40. PubMed ID: 15325893
    [Abstract] [Full Text] [Related]

  • 19. Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques.
    McConville C, Smith JM, McCoy CF, Srinivasan P, Mitchell J, Holder A, Otten RA, Butera S, Doncel GF, Friend DR, Malcolm RK.
    Drug Deliv Transl Res; 2015 Feb 01; 5(1):27-37. PubMed ID: 25787337
    [Abstract] [Full Text] [Related]

  • 20. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
    O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.
    Sex Transm Dis; 2010 Feb 01; 37(2):100-4. PubMed ID: 19823111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.